James Francis Doherty

US Patent:

7196095, Mar 27, 2007

Filed:

Jun 21, 2002

Appl. No.:

10/477367

Inventors:

Tesfaye Biftu - Westfield NJ, US
Richard Beresis - Matawan NJ, US
Richard Berger - Cranford NJ, US
Steven L. Colletti - Princeton Junction NJ, US
James B. Doherty - Montvale NJ, US
Dennis D. Feng - Branchburg Township NJ, US
Dennis M. Schmatz - Cranford NJ, US
Xiaoxia Qian - New York NY, US
David A. Claremon - Maple Glen PA, US
Nigel J. Liverton - Harleysville PA, US
Charles J. McIntyre - Lansdale PA, US
Ernest W. Kovacs - Weehawken NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07D 403/04
C07D 403/14
C07D 417/04
C07D 417/14
A61K 31/506
A61P 19/02

US Classification:

514275, 514243, 5142591, 544331, 544184, 544281

Abstract:

Compounds of formula (I) and pharmaceutically acceptable salts thereof are useful in the treatment of cytokine mediated diseases such as arthritis and in the treatment and/or prevention of protozoal diseases such as coccidiosis.

US Patent:

7410992, Aug 12, 2008

Filed:

Aug 31, 2004

Appl. No.:

10/569921

Inventors:

Meng Hsin Chen - Westfield NJ, US
James B. Doherty - Montvale NJ, US
Luping Liu - Plainsboro NJ, US
Swaminathan Natarajan - Scotch Plains NJ, US
Robert M. Tynebor - Woodbridge NJ, US

Assignee:

Merck & Co. Inc. - Rahway NJ

International Classification:

A61K 31/416
C07D 231/54

US Classification:

514406, 5483581, 5483601, 5483611, 5483615, 514403

Abstract:

This invention relates to potent potassium channel blocker compounds of Formula (I) or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans, or a pharmaceutically acceptable salt, in vivo hydrolysable ester, enantiomer, diastereomer or mixture thereof: formula (II) represents Caryl or Cheterocyclyl, said aryl or heterocyclyl optionally substituted with 1-3 groups selected from R; Z represents (CH)PO(OR)(OR*).

US Patent:

7482345, Jan 27, 2009

Filed:

Nov 21, 2006

Appl. No.:

11/602782

Inventors:

Meng-Hsin Chen - Rahway NJ, US
James B. Doherty - Rahway NJ, US
Robert Tynebor - West Point PA, US

International Classification:

A61K 31/53
A61K 31/5025
A61K 31/4985
A61K 31/4375
C07D 401/06
C07D 401/12
C07D 401/10
C07D 401/14
C07D 421/06
C07D 421/10
C07D 421/12
C07D 421/14
C07D 487/04
C07D 471/04

US Classification:

514248, 544349, 544235, 544183, 544224, 546138, 546345, 546 14

Abstract:

Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof:.

US Patent:

7494983, Feb 24, 2009

Filed:

Aug 31, 2004

Appl. No.:

10/570231

Inventors:

Meng Hsin Chen - Westfield NJ, US
James B. Doherty - Montvale NJ, US
Luping Liu - Plainsboro NJ, US
Swaminathan Natarajan - Scotch Plains NJ, US
Robert M. Tynebor - Woodbridge NJ, US

Assignee:

Merck & Co. Inc. - Rahway NJ

International Classification:

A61K 31/675
A61K 31/4439
C07F 9/06

US Classification:

514 80, 514 89, 514338, 514406, 546 22, 546 24, 548113

Abstract:

This invention relates to potent potassium channel blocker compounds of structural Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

US Patent:

7879875, Feb 1, 2011

Filed:

Aug 8, 2006

Appl. No.:

11/990050

Inventors:

Meng-Hsin Chen - Westfield NJ, US
James B. Doherty - Montvale NJ, US
Robert Tynebor - Hatfield PA, US
Swaminathan R. Natarajan - Scotch Plains NJ, US
Zhen Li - Scotch Plains NJ, US
Soumya P. Sahoo - Old Bridge NJ, US

Assignee:

Merk Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/4375
C07D 455/02

US Classification:

514306, 546138

Abstract:

Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: (I) are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.

US Patent:

20040138502, Jul 15, 2004

Filed:

Feb 25, 2004

Appl. No.:

10/469824

Inventors:

Stephen Traynelis - Decatur GA, US
Dennis Liotta - Atlanta GA, US
James Snyder - Atlanta GA, US
Yesim Altas - Decatur GA, US
David Mott - Tucker GA, US
James Doherty - Landenberg PA, US
Raymond Dingledine - Atlanta GA, US

International Classification:

C 07C 3 9/29

US Classification:

564/092000, 564/099000

Abstract:

NMDA receptor blockers, including pH-sensitive NMDA receptor blockers, are provided as neuroprotective drugs that are useful in stroke, traumatic brain injury, epilepsy, and other neurologic events that involve acidification of brain or spinal cord tissue. Compositions and methods of this invention are used for treating neurodegeneration resulting from NMDA receptor activation. The compounds described herein have enhanced activity in brain tissue having lower-than normal pH due to pathological conditions such as hypoxia resulting from stroke, traumatic brain injury, global ischemia tat may occur during cardiac surgery, hypoxia tat may occur following cessation of breathing, pre-eclampsia, spinal cord trauma, epilepsy, chronic pain, vascular dementia and glioma tumors. Compounds described herein are also useful in preventing neurodegeneration in patients with Parkinson's Alzheimer's, Huntington's chorea, ALS, and other neurodegenerative conditions known to the art to be responsive to treatment using NMDA receptor blockers. Preferably the compounds provided herein are allosteric NMDA inhibitors.

US Patent:

20050256117, Nov 17, 2005

Filed:

Jun 11, 2003

Appl. No.:

10/511636

Inventors:

Meng Hsin Chen - Westfield NJ, US
Luping Liu - Palainsboro NJ, US
Peter Meinke - Plainfield NJ, US
Ravi Natarajan - Scotch Plains NJ, US
William Parsons - Belle Mead NJ, US
Min Shu - Green Brook NJ, US
John Stelmach - Westfield NJ, US
Harold Wood - Westfield NJ, US
Fengqi Zhang - Edison NJ, US
David Wisnoski - Lansdale PA, US
James Doherty - Montvale NJ, US

International Classification:

A61K031/5377
A61K031/4439
A61K031/427
C07D417/02
C07D413/02
C07D043/02

US Classification:

514233500, 514370000, 548181000, 514337000, 546270700, 544143000

Abstract:

This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

US Patent:

20060148805, Jul 6, 2006

Filed:

Jun 25, 2004

Appl. No.:

10/561571

Inventors:

Meng Hsin Chen - Westfield NJ, US
James Doherty - Montvale NJ, US
Luping Liu - Plainsboro NJ, US
Swaminathan Natarajan - Scotch Plains NJ, US
Min Shu - Greenbrook NJ, US

International Classification:

A61K 31/522
A61K 31/503
A61K 31/498
A61K 31/4184
C07D 473/10
C07D 471/02
C07D 487/02

US Classification:

514248000, 514249000, 514263380, 514303000, 514394000, 544236000, 544276000, 544330000, 546117000, 548305400

Abstract:

This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.